Table 2.
ID | Age, Y | Gender | Race | Type of transplant | Cause of ESRD | cPRA | DSA | Induction | Time to rejection (months) | Type of TCMR | Reason for rejection |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 60–65 | Male | African American | DDRT | HTN | 0 | DR53 Flowcytometric cross match level |
Thymoglobulin | 19 | 2A | BK viremia/lower immunosuppression |
2 | 30–35 | Male | White | DDRT | Diabetic nephropathy | 0 | De novo DQA5 Below flowcytometric crossmatch |
Thymoglobulin | 11 | 1A | Lower dose of MMF |
3 | 20–25 | Female | White | LRT | IgA nephropathy | 0 | De novo DSA: DR7, DR53, DQA3, DQB2, and DQB7 positive cytotoxic crossmatch | Thymoglobulin | 21 | 1B | |
4 | 40–45 | Female | White | LRT | Lupus nephritis | 9% | Negative | Thymoglobulin | 1 | 1A | Lower dose of MMF |
5 | 45–50 | Female | Asian | LRT | Unclear Etiology | 10% | Negative | IL2 antagonist | 3 | 1A | |
6 | 55–60 | Female | Asian | DDRT | Chronic glomerular nephropathy | 0 | Negative | IL2 antagonist | 3 | 1A | |
7 | 40–45 | Female | Asian | LRT | Diabetic nephropathy | 70% | Negative | IL2 antagonist | 35 | 1A |
cPRA calculated Panel Reactive Antibodies, DSA Donor Specific Antibodies, TCMD T cell mediated rejection, DDRT deceased donor renal transplant, HTN hypertension, MMF mycophenolate mofetil, LRT living donor renal transplant